ESLOF:OTC-EssilorLuxottica Société anonyme (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 283.9

Change

+8.10 (+2.94)%

Market Cap

USD 125.52B

Volume

524.00

Analyst Target

USD 160.21
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-02 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

+0.19 (+0.14%)

USD 126.80B
HOCPF HOYA Corporation

-0.48 (-0.40%)

USD 43.54B
HOCPY Hoya Corp

-0.46 (-0.39%)

USD 41.79B
TRUMF Terumo Corporation

+0.12 (+0.61%)

USD 28.03B
SDMHF Sartorius Stedim Biotech S.A

N/A

USD 22.03B
CLPBY Coloplast A

-0.04 (-0.42%)

USD 21.79B
CLPBF Coloplast A/S

N/A

USD 21.70B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 21.56B
SAUHF Straumann Holding AG

+9.65 (+7.86%)

USD 20.49B
SUVPF Sartorius Aktiengesellschaft

N/A

USD 16.40B

ETFs Containing ESLOF

C068:F 2.63 % 0.00 %

N/A

N/A
C068:XETRA 2.63 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.17% 78% C+ 67% D+
Dividend Return 1.72% 78% C+ 40% F
Total Return 19.88% 79% B- 69% C-
Trailing 12 Months  
Capital Gain 25.84% 84% B 75% C
Dividend Return 1.83% 72% C 25% F
Total Return 27.67% 87% B+ 75% C
Trailing 5 Years  
Capital Gain 106.92% 96% N/A 83% B
Dividend Return 14.42% 91% A- 37% F
Total Return 121.35% 93% A 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 15.81% 79% B- 66% D+
Dividend Return 17.52% 77% C+ 65% D
Total Return 1.71% 61% D- 38% F
Risk Return Profile  
Volatility (Standard Deviation) 20.77% 87% B+ 84% B
Risk Adjusted Return 84.33% 98% N/A 96% N/A
Market Capitalization 125.52B 98% N/A 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.